Viragen, Inc. Licenses Multiferon to Kuhnil Pharm Co. Ltd.

Strategic Insights -

Viragen, Inc. has entered into a 10-year license agreement with Kuhnil Pharm Co. Ltd. to distribute its multi-subtype, natural human alpha interferon, Multiferon, in South Korea. Under the agreement, Kuhnil Pharm will provide exclusive marketing rights to the drug in exchange for a small up-front license fee. The South Korean regulatory approval process, led by the Korean health regulatory authority, KFDA, is expected to take approximately 12 months. This partnership expands Viragen's global presence, with operations in the U.S., Scotland, and Sweden, and highlights the growing demand for innovative cancer therapies.

Key Takeaways:

  • Viragen, Inc. licensed its multi-subtype, natural human alpha interferon, Multiferon, to Kuhnil Pharm Co. Ltd. for distribution in South Korea.
  • The 10-year license agreement grants Kuhnil Pharm exclusive marketing rights to Multiferon in South Korea in exchange for a small up-front license fee.
  • Kuhnil Pharm, a privately held company established in 1951 in Seoul, South Korea, will take necessary measures to achieve regulatory approval for Multiferon in South Korea within the next 12 months.
  • The partnership expands Viragen's global presence, with operations in the U.S., Scotland, and Sweden.
  • Multiferon is approved for sale in ten international markets for the first-line or rescue therapy of a broad range of infectious diseases and cancers.
  • Viragen filed an application in Sweden earlier this year for expanded approval of Multiferon to include the first-line adjuvant treatment of high-risk malignant melanoma.
  • Kuhnil Pharm has a network of clinics, physicians, and hospitals with over 300 sales representatives, focusing on oncology in Korea.

Statistics:

  • The South Korean regulatory approval process for Multiferon is expected to take approximately 12 months.
  • Viragen has operations in the U.S., Scotland, and Sweden.
  • Multiferon is approved for sale in ten international markets.
  • Kuhnil Pharm has a network of clinics, physicians, and hospitals with over 300 sales representatives.

Sources:

  • Viragen, Inc. (press release)
  • Kuhnil Pharm Co. Ltd. (company profile)
  • Science Letter via NewsRx.com (article, 2006, no specific date)